Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease.

Mann AP, Scodeller P, Hussain S, Braun GB, Mölder T, Toome K, Ambasudhan R, Teesalu T, Lipton SA, Ruoslahti E.

Nat Commun. 2017 Nov 10;8(1):1403. doi: 10.1038/s41467-017-01096-0.

2.

Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide.

Scodeller P, Simón-Gracia L, Kopanchuk S, Tobi A, Kilk K, Säälik P, Kurm K, Squadrito ML, Kotamraju VR, Rinken A, De Palma M, Ruoslahti E, Teesalu T.

Sci Rep. 2017 Nov 7;7(1):14655. doi: 10.1038/s41598-017-14709-x.

3.

Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy.

Cureton N, Korotkova I, Baker B, Greenwood S, Wareing M, Kotamraju VR, Teesalu T, Cellesi F, Tirelli N, Ruoslahti E, Aplin JD, Harris LK.

Theranostics. 2017 Aug 29;7(15):3715-3731. doi: 10.7150/thno.19678. eCollection 2017.

4.

Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment.

Sharma S, Mann AP, Mölder T, Kotamraju VR, Mattrey R, Teesalu T, Ruoslahti E.

J Control Release. 2017 Dec 28;268:49-56. doi: 10.1016/j.jconrel.2017.10.006. Epub 2017 Oct 13.

PMID:
29030222
5.

Ratiometric in vivo auditioning of targeted silver nanoparticles.

Toome K, Willmore AA, Paiste P, Tobi A, Sugahara KN, Kirsimäe K, Ruoslahti E, Braun GB, Teesalu T.

Nanoscale. 2017 Jul 20;9(28):10094-10100. doi: 10.1039/c7nr04056c.

PMID:
28695222
6.

Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.

Hunt H, Simón-Gracia L, Tobi A, Kotamraju VR, Sharma S, Nigul M, Sugahara KN, Ruoslahti E, Teesalu T.

J Control Release. 2017 Aug 28;260:142-153. doi: 10.1016/j.jconrel.2017.06.005. Epub 2017 Jun 8.

PMID:
28603028
7.

Hyaluronan-binding peptide for targeting peritoneal carcinomatosis.

Ikemoto H, Lingasamy P, Anton Willmore AM, Hunt H, Kurm K, Tammik O, Scodeller P, Simón-Gracia L, Kotamraju VR, Lowy AM, Sugahara KN, Teesalu T.

Tumour Biol. 2017 May;39(5):1010428317701628. doi: 10.1177/1010428317701628.

8.

Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth.

Sharma S, Kotamraju VR, Mölder T, Tobi A, Teesalu T, Ruoslahti E.

Nano Lett. 2017 Mar 8;17(3):1356-1364. doi: 10.1021/acs.nanolett.6b03815. Epub 2017 Feb 17.

PMID:
28178415
9.

iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Simón-Gracia L, Hunt H, Scodeller P, Gaitzsch J, Kotamraju VR, Sugahara KN, Tammik O, Ruoslahti E, Battaglia G, Teesalu T.

Biomaterials. 2016 Oct;104:247-57. doi: 10.1016/j.biomaterials.2016.07.023. Epub 2016 Jul 20.

10.

Tumor-homing peptides as tools for targeted delivery of payloads to the placenta.

King A, Ndifon C, Lui S, Widdows K, Kotamraju VR, Agemy L, Teesalu T, Glazier JD, Cellesi F, Tirelli N, Aplin JD, Ruoslahti E, Harris LK.

Sci Adv. 2016 May 6;2(5):e1600349. doi: 10.1126/sciadv.1600349. eCollection 2016 May.

11.

A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries.

Mann AP, Scodeller P, Hussain S, Joo J, Kwon E, Braun GB, Mölder T, She ZG, Kotamraju VR, Ranscht B, Krajewski S, Teesalu T, Bhatia S, Sailor MJ, Ruoslahti E.

Nat Commun. 2016 Jun 28;7:11980. doi: 10.1038/ncomms11980.

12.

Rab11 and Lysotracker Markers Reveal Correlation between Endosomal Pathways and Transfection Efficiency of Surface-Functionalized Cationic Liposome-DNA Nanoparticles.

Majzoub RN, Wonder E, Ewert KK, Kotamraju VR, Teesalu T, Safinya CR.

J Phys Chem B. 2016 Jul 7;120(26):6439-53. doi: 10.1021/acs.jpcb.6b04441. Epub 2016 Jun 3.

13.

Urokinase-controlled tumor penetrating peptide.

Braun GB, Sugahara KN, Yu OM, Kotamraju VR, Mölder T, Lowy AM, Ruoslahti E, Teesalu T.

J Control Release. 2016 Jun 28;232:188-95. doi: 10.1016/j.jconrel.2016.04.027. Epub 2016 Apr 19.

14.

New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.

Paasonen L, Sharma S, Braun GB, Kotamraju VR, Chung TD, She ZG, Sugahara KN, Yliperttula M, Wu B, Pellecchia M, Ruoslahti E, Teesalu T.

Chembiochem. 2016 Apr 1;17(7):570-5. doi: 10.1002/cbic.201500564. Epub 2016 Feb 19.

15.

Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy.

Simón-Gracia L, Hunt H, Scodeller PD, Gaitzsch J, Braun GB, Willmore AM, Ruoslahti E, Battaglia G, Teesalu T.

Mol Cancer Ther. 2016 Apr;15(4):670-9. doi: 10.1158/1535-7163.MCT-15-0713-T. Epub 2016 Feb 15.

16.

Synthesis of linear and cyclic peptide-PEG-lipids for stabilization and targeting of cationic liposome-DNA complexes.

Ewert KK, Kotamraju VR, Majzoub RN, Steffes VM, Wonder EA, Teesalu T, Ruoslahti E, Safinya CR.

Bioorg Med Chem Lett. 2016 Mar 15;26(6):1618-1623. doi: 10.1016/j.bmcl.2016.01.079. Epub 2016 Feb 4.

17.

Targeted silver nanoparticles for ratiometric cell phenotyping.

Willmore AM, Simón-Gracia L, Toome K, Paiste P, Kotamraju VR, Mölder T, Sugahara KN, Ruoslahti E, Braun GB, Teesalu T.

Nanoscale. 2016 Apr 28;8(17):9096-101. doi: 10.1039/c5nr07928d.

18.

A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.

Sugahara KN, Scodeller P, Braun GB, de Mendoza TH, Yamazaki CM, Kluger MD, Kitayama J, Alvarez E, Howell SB, Teesalu T, Ruoslahti E, Lowy AM.

J Control Release. 2015 Aug 28;212:59-69. doi: 10.1016/j.jconrel.2015.06.009. Epub 2015 Jun 11.

19.

Ultrasound molecular imaging of tumor angiogenesis with a neuropilin-1-targeted microbubble.

Zhang H, Tam S, Ingham ES, Mahakian LM, Lai CY, Tumbale SK, Teesalu T, Hubbard NE, Borowsky AD, Ferrara KW.

Biomaterials. 2015 Jul;56:104-13. doi: 10.1016/j.biomaterials.2015.03.043. Epub 2015 Apr 16.

20.

Tumor-penetrating iRGD peptide inhibits metastasis.

Sugahara KN, Braun GB, de Mendoza TH, Kotamraju VR, French RP, Lowy AM, Teesalu T, Ruoslahti E.

Mol Cancer Ther. 2015 Jan;14(1):120-8. doi: 10.1158/1535-7163.MCT-14-0366. Epub 2014 Nov 12.

21.

Reprogramming human retinal pigmented epithelial cells to neurons using recombinant proteins.

Hu Q, Chen R, Teesalu T, Ruoslahti E, Clegg DO.

Stem Cells Transl Med. 2014 Dec;3(12):1526-34. doi: 10.5966/sctm.2014-0038. Epub 2014 Oct 8.

22.

An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability.

Pang HB, Braun GB, Friman T, Aza-Blanc P, Ruidiaz ME, Sugahara KN, Teesalu T, Ruoslahti E.

Nat Commun. 2014 Oct 3;5:4904. doi: 10.1038/ncomms5904.

23.

Etchable plasmonic nanoparticle probes to image and quantify cellular internalization.

Braun GB, Friman T, Pang HB, Pallaoro A, Hurtado de Mendoza T, Willmore AM, Kotamraju VR, Mann AP, She ZG, Sugahara KN, Reich NO, Teesalu T, Ruoslahti E.

Nat Mater. 2014 Sep;13(9):904-11. doi: 10.1038/nmat3982. Epub 2014 Jun 8.

24.

A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity.

Pang HB, Braun GB, She ZG, Kotamraju VR, Sugahara KN, Teesalu T, Ruoslahti E.

J Control Release. 2014 Feb 10;175:48-53. doi: 10.1016/j.jconrel.2013.12.006. Epub 2013 Dec 15.

25.

Tumor-penetrating peptides.

Teesalu T, Sugahara KN, Ruoslahti E.

Front Oncol. 2013 Aug 27;3:216. doi: 10.3389/fonc.2013.00216. eCollection 2013.

26.

Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.

Sánchez-Martín D, Martínez-Torrecuadrada J, Teesalu T, Sugahara KN, Alvarez-Cienfuegos A, Ximénez-Embún P, Fernández-Periáñez R, Martín MT, Molina-Privado I, Ruppen-Cañás I, Blanco-Toribio A, Cañamero M, Cuesta AM, Compte M, Kremer L, Bellas C, Alonso-Camino V, Guijarro-Muñoz I, Sanz L, Ruoslahti E, Alvarez-Vallina L.

Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13791-6. doi: 10.1073/pnas.1300013110. Epub 2013 Aug 5.

27.

Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor.

Zanuy D, Kotla R, Nussinov R, Teesalu T, Sugahara KN, Alemán C, Haspel N.

J Struct Biol. 2013 May;182(2):78-86. doi: 10.1016/j.jsb.2013.02.006. Epub 2013 Feb 24.

PMID:
23462097
28.

The non-peptidic part determines the internalization mechanism and intracellular trafficking of peptide amphiphiles.

Missirlis D, Teesalu T, Black M, Tirrell M.

PLoS One. 2013;8(1):e54611. doi: 10.1371/journal.pone.0054611. Epub 2013 Jan 17.

29.

Application of a proapoptotic peptide to intratumorally spreading cancer therapy.

Chen R, Braun GB, Luo X, Sugahara KN, Teesalu T, Ruoslahti E.

Cancer Res. 2013 Feb 15;73(4):1352-61. doi: 10.1158/0008-5472.CAN-12-1979. Epub 2012 Dec 17.

30.

De novo design of a tumor-penetrating peptide.

Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, Bordignon C, Traversari C, Rizzardi GP, Ruoslahti E.

Cancer Res. 2013 Jan 15;73(2):804-12. doi: 10.1158/0008-5472.CAN-12-1668. Epub 2012 Nov 14.

31.

Mapping of vascular ZIP codes by phage display.

Teesalu T, Sugahara KN, Ruoslahti E.

Methods Enzymol. 2012;503:35-56. doi: 10.1016/B978-0-12-396962-0.00002-1. Review.

PMID:
22230564
32.

Transtumoral targeting enabled by a novel neuropilin-binding peptide.

Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, Hamzah J, Ruoslahti E.

Oncogene. 2012 Aug 16;31(33):3754-63. doi: 10.1038/onc.2011.537. Epub 2011 Dec 19.

PMID:
22179825
33.

Selection of phage-displayed peptides on live adherent cells in microfluidic channels.

Wang J, Liu Y, Teesalu T, Sugahara KN, Kotamrajua VR, Adams JD, Ferguson BS, Gong Q, Oh SS, Csordas AT, Cho M, Ruoslahti E, Xiao Y, Soh HT.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6909-14. doi: 10.1073/pnas.1014753108. Epub 2011 Apr 12.

34.

A high-throughput label-free nanoparticle analyser.

Fraikin JL, Teesalu T, McKenney CM, Ruoslahti E, Cleland AN.

Nat Nanotechnol. 2011 May;6(5):308-13. doi: 10.1038/nnano.2011.24. Epub 2011 Mar 6.

PMID:
21378975
35.

Binding of a C-end rule peptide to the neuropilin-1 receptor: a molecular modeling approach.

Haspel N, Zanuy D, Nussinov R, Teesalu T, Ruoslahti E, Aleman C.

Biochemistry. 2011 Mar 15;50(10):1755-62. doi: 10.1021/bi101662j. Epub 2011 Feb 14.

36.

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E.

Science. 2010 May 21;328(5981):1031-5. doi: 10.1126/science.1183057. Epub 2010 Apr 8.

37.

Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E.

Cancer Cell. 2009 Dec 8;16(6):510-20. doi: 10.1016/j.ccr.2009.10.013.

38.

C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.

Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62. doi: 10.1073/pnas.0908201106. Epub 2009 Sep 2.

39.

EFA6A encodes two isoforms with distinct biological activities in neuronal cells.

Sironi C, Teesalu T, Muggia A, Fontana G, Marino F, Savaresi S, Talarico D.

J Cell Sci. 2009 Jun 15;122(Pt 12):2108-18. doi: 10.1242/jcs.042325.

40.

Fourth meeting of the European Network of Research Tissue Banks - future strategy to increase collaborations in the supply of human tissue for biomedical research.

Orr S, Alexandre E, Clark BJ, Gray N, Helin H, Ravid R, Read M, Richert L, Roosipuu R, Jonsson-Rylander AC, Syring C, Teesalu T, Thasler WE, Trafford J, Van Der Valk J, Weiss TS, Womack C, Ylikomi T.

Cell Tissue Bank. 2005;6(2):131-8.

PMID:
15909101
41.

Characterization of the NF2 protein merlin and the ERM protein ezrin in human, rat, and mouse central nervous system.

Grönholm M, Teesalu T, Tyynelä J, Piltti K, Böhling T, Wartiovaara K, Vaheri A, Carpén O.

Mol Cell Neurosci. 2005 Apr;28(4):683-93.

PMID:
15797715
42.

Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system.

Teesalu T, Kulla A, Simisker A, Sirén V, Lawrence DA, Asser T, Vaheri A.

Thromb Haemost. 2004 Aug;92(2):358-68.

PMID:
15269833
43.

The establishment of a network of European human research tissue banks.

Orr S, Alexandre E, Clark B, Combes R, Fels LM, Gray N, Jönsson-Rylander AC, Helin H, Koistinen J, Oinonen T, Richert L, Ravid R, Salonen J, Teesalu T, Thasler W, Trafford J, Van Der Valk J, Von Versen R, Weiss T, Womack C, Ylikomi T.

Cell Tissue Bank. 2002;3(2):133-7.

PMID:
15256890
44.

Merlin links to the cAMP neuronal signaling pathway by anchoring the RIbeta subunit of protein kinase A.

Grönholm M, Vossebein L, Carlson CR, Kuja-Panula J, Teesalu T, Alfthan K, Vaheri A, Rauvala H, Herberg FW, Taskén K, Carpén O.

J Biol Chem. 2003 Oct 17;278(42):41167-72. Epub 2003 Aug 1.

45.

Establishment and characterisation of human papillomavirus type 16 DNA immortalised human tonsillar epithelial cell lines.

Chen RW, Aalto Y, Teesalu T, Dürst M, Knuutila S, Aaltonen LM, Vaheri A.

Eur J Cancer. 2003 Mar;39(5):698-707.

PMID:
12628851
46.

Analysis of the TP53 gene in laser-microdissected glioblastoma vasculature.

Kulla A, Burkhardt K, Meyer-Puttlitz B, Teesalu T, Asser T, Wiestler OD, Becker AJ.

Acta Neuropathol. 2003 Apr;105(4):328-32. Epub 2003 Feb 14.

PMID:
12624785
47.

Tissue plasminogen activator as a key effector in neurobiology and neuropathology.

Teesalu T, Kulla A, Asser T, Koskiniemi M, Vaheri A.

Biochem Soc Trans. 2002 Apr;30(2):183-9. Review.

PMID:
12023848
48.
49.

Trophoblast giant cells express NF-kappa B2 during early mouse development.

Muggia A, Teesalu T, Neri A, Blasi F, Talarico D.

Dev Genet. 1999;25(1):23-30.

PMID:
10402669
50.

Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation.

Teesalu T, Masson R, Basset P, Blasi F, Talarico D.

Dev Dyn. 1999 Mar;214(3):248-58.

Supplemental Content

Loading ...
Support Center